21:28 , Jul 19, 2019 |  BC Extra  |  Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation  Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
00:38 , Jun 21, 2019 |  BC Innovations  |  Tools & Techniques

A human CRISPR-like system adds a new approach to regulating translation

A new system modeled on CRISPR and made entirely of human proteins is the latest strategy to intervene in gene control at the RNA translation level. The technology could bring higher levels of precision and...
22:15 , Jun 17, 2019 |  BC Extra  |  Company News

Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on...
00:43 , Jun 11, 2019 |  BC Extra  |  Clinical News

Provention could use data from diabetes consortia to bring teplizumab to market faster

Results from a Phase II study showing Provention’s anti-CD3 mAb teplizumab delayed the onset of Type I diabetes in high-risk individuals raised the possibility of a faster path to market than the biotech’s Phase III...
02:23 , May 18, 2019 |  BioCentury  |  Product Development

AAVs on the brink: Charting the clinical landscape of in vivo gene therapies

Gene therapy is finally teetering on the edge of becoming a drug development mainstay, with at least nine AAV-based therapies in Phase III or II/III testing. An analysis of the AAV therapies in the clinic...
01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:54 , Nov 9, 2018 |  BioCentury  |  Product Development

Cashing out CVOT

Whether or how much diabetes companies will save by dropping postmarket cardiovascular outcomes trials, if FDA follows the advice of its advisory committee, could boil down to what target they are pursuing and whether they...
20:03 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Orchard achieves $1.2B valuation with $200M IPO

Orchard Therapeutics Ltd. (NASDAQ:ORTX) raised $200 million on Oct. 31 in an IPO that priced at the bottom of its proposed range, but sold more ADSs than proposed. The IPO price values the company at...